2023
Targeting the NLRP3 inflammasome and associated cytokines in scleroderma associated interstitial lung disease
Woo S, Gandhi S, Ghincea A, Saber T, Lee C, Ryu C. Targeting the NLRP3 inflammasome and associated cytokines in scleroderma associated interstitial lung disease. Frontiers In Cell And Developmental Biology 2023, 11: 1254904. PMID: 37849737, PMCID: PMC10577231, DOI: 10.3389/fcell.2023.1254904.Peer-Reviewed Original ResearchSSc-ILDNLRP3 inflammasomeScleroderma-Associated Interstitial Lung DiseaseAssociated interstitial lung diseaseInterstitial lung diseaseNormal lung architectureImproved treatment optionsProgressive fibrotic replacementNovel pathophysiologic insightsComplex rheumatic diseasesImmune dysregulationPathophysiologic insightsRheumatic diseasesClinical benefitIL-18IL-1βLung diseaseTreatment optionsFibrotic replacementLung architectureNovel therapiesClinical significanceInnate immunityDiseaseAdditional studies
2019
New Applications of Old Drugs as Novel Therapies in Idiopathic Pulmonary Fibrosis. Metformin, Hydroxychloroquine, and Thyroid Hormone
Manning EP, Losier A, Emeagwali N, Ryu C, Honiden S. New Applications of Old Drugs as Novel Therapies in Idiopathic Pulmonary Fibrosis. Metformin, Hydroxychloroquine, and Thyroid Hormone. American Journal Of Respiratory And Critical Care Medicine 2019, 199: 1561-1563. PMID: 30822095, PMCID: PMC7051474, DOI: 10.1164/rccm.201809-1700rr.Peer-Reviewed Original Research